nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefenamic acid—AKR1C3—Doxorubicin—liver cancer	0.519	0.819	CbGbCtD
Mefenamic acid—CYP2C8—Sorafenib—liver cancer	0.0676	0.107	CbGbCtD
Mefenamic acid—CYP2C9—Sorafenib—liver cancer	0.0471	0.0744	CbGbCtD
Mefenamic acid—Acetylsalicylic acid—TP53—liver cancer	0.00197	0.427	CrCbGaD
Mefenamic acid—Tinnitus—Sorafenib—liver cancer	0.00091	0.00585	CcSEcCtD
Mefenamic acid—Arrhythmia—Sorafenib—liver cancer	0.000872	0.00561	CcSEcCtD
Mefenamic acid—Alopecia—Sorafenib—liver cancer	0.000862	0.00555	CcSEcCtD
Mefenamic acid—Mental disorder—Sorafenib—liver cancer	0.000855	0.0055	CcSEcCtD
Mefenamic acid—Jaundice cholestatic—Epirubicin—liver cancer	0.000817	0.00526	CcSEcCtD
Mefenamic acid—Rectal haemorrhage—Epirubicin—liver cancer	0.000795	0.00511	CcSEcCtD
Mefenamic acid—Anaemia—Sorafenib—liver cancer	0.000785	0.00505	CcSEcCtD
Mefenamic acid—Glossitis—Epirubicin—liver cancer	0.000779	0.00501	CcSEcCtD
Mefenamic acid—Oliguria—Epirubicin—liver cancer	0.000779	0.00501	CcSEcCtD
Mefenamic acid—Angioedema—Sorafenib—liver cancer	0.000776	0.00499	CcSEcCtD
Mefenamic acid—Syncope—Sorafenib—liver cancer	0.000762	0.0049	CcSEcCtD
Mefenamic acid—Leukopenia—Sorafenib—liver cancer	0.00076	0.00489	CcSEcCtD
Mefenamic acid—Ulcer—Epirubicin—liver cancer	0.000759	0.00488	CcSEcCtD
Mefenamic acid—Jaundice cholestatic—Doxorubicin—liver cancer	0.000756	0.00486	CcSEcCtD
Mefenamic acid—Loss of consciousness—Sorafenib—liver cancer	0.000747	0.0048	CcSEcCtD
Mefenamic acid—Rectal haemorrhage—Doxorubicin—liver cancer	0.000736	0.00473	CcSEcCtD
Mefenamic acid—Hypertension—Sorafenib—liver cancer	0.000733	0.00472	CcSEcCtD
Mefenamic acid—Glossitis—Doxorubicin—liver cancer	0.000721	0.00464	CcSEcCtD
Mefenamic acid—Oliguria—Doxorubicin—liver cancer	0.000721	0.00464	CcSEcCtD
Mefenamic acid—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.000718	0.00462	CcSEcCtD
Mefenamic acid—Dry mouth—Sorafenib—liver cancer	0.000707	0.00455	CcSEcCtD
Mefenamic acid—Eructation—Epirubicin—liver cancer	0.000706	0.00454	CcSEcCtD
Mefenamic acid—Ulcer—Doxorubicin—liver cancer	0.000703	0.00452	CcSEcCtD
Mefenamic acid—Melaena—Epirubicin—liver cancer	0.000702	0.00451	CcSEcCtD
Mefenamic acid—Cystitis noninfective—Epirubicin—liver cancer	0.000702	0.00451	CcSEcCtD
Mefenamic acid—Cystitis—Epirubicin—liver cancer	0.000694	0.00446	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Sorafenib—liver cancer	0.000693	0.00446	CcSEcCtD
Mefenamic acid—Colitis—Epirubicin—liver cancer	0.00069	0.00443	CcSEcCtD
Mefenamic acid—Infection—Sorafenib—liver cancer	0.000689	0.00443	CcSEcCtD
Mefenamic acid—Shock—Sorafenib—liver cancer	0.000682	0.00439	CcSEcCtD
Mefenamic acid—Fluid retention—Epirubicin—liver cancer	0.000682	0.00439	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Sorafenib—liver cancer	0.000679	0.00437	CcSEcCtD
Mefenamic acid—Aplastic anaemia—Epirubicin—liver cancer	0.000674	0.00434	CcSEcCtD
Mefenamic acid—Skin disorder—Sorafenib—liver cancer	0.000673	0.00433	CcSEcCtD
Mefenamic acid—Anorexia—Sorafenib—liver cancer	0.000661	0.00425	CcSEcCtD
Mefenamic acid—Oesophagitis—Epirubicin—liver cancer	0.000656	0.00422	CcSEcCtD
Mefenamic acid—Coma—Epirubicin—liver cancer	0.000656	0.00422	CcSEcCtD
Mefenamic acid—Eructation—Doxorubicin—liver cancer	0.000653	0.0042	CcSEcCtD
Mefenamic acid—Bladder pain—Epirubicin—liver cancer	0.000649	0.00418	CcSEcCtD
Mefenamic acid—Ecchymosis—Epirubicin—liver cancer	0.000649	0.00418	CcSEcCtD
Mefenamic acid—Melaena—Doxorubicin—liver cancer	0.000649	0.00417	CcSEcCtD
Mefenamic acid—Cystitis noninfective—Doxorubicin—liver cancer	0.000649	0.00417	CcSEcCtD
Mefenamic acid—Cystitis—Doxorubicin—liver cancer	0.000642	0.00413	CcSEcCtD
Mefenamic acid—Colitis—Doxorubicin—liver cancer	0.000638	0.0041	CcSEcCtD
Mefenamic acid—Fluid retention—Doxorubicin—liver cancer	0.000631	0.00406	CcSEcCtD
Mefenamic acid—Aplastic anaemia—Doxorubicin—liver cancer	0.000624	0.00401	CcSEcCtD
Mefenamic acid—Sepsis—Epirubicin—liver cancer	0.000623	0.00401	CcSEcCtD
Mefenamic acid—Dyspnoea—Sorafenib—liver cancer	0.000618	0.00398	CcSEcCtD
Mefenamic acid—Lymphadenopathy—Epirubicin—liver cancer	0.000611	0.00393	CcSEcCtD
Mefenamic acid—Dyspepsia—Sorafenib—liver cancer	0.00061	0.00393	CcSEcCtD
Mefenamic acid—Oesophagitis—Doxorubicin—liver cancer	0.000607	0.00391	CcSEcCtD
Mefenamic acid—Coma—Doxorubicin—liver cancer	0.000607	0.00391	CcSEcCtD
Mefenamic acid—Decreased appetite—Sorafenib—liver cancer	0.000603	0.00388	CcSEcCtD
Mefenamic acid—Ecchymosis—Doxorubicin—liver cancer	0.000601	0.00386	CcSEcCtD
Mefenamic acid—Bladder pain—Doxorubicin—liver cancer	0.000601	0.00386	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Sorafenib—liver cancer	0.000599	0.00385	CcSEcCtD
Mefenamic acid—Photosensitivity—Epirubicin—liver cancer	0.000594	0.00382	CcSEcCtD
Mefenamic acid—Constipation—Sorafenib—liver cancer	0.000593	0.00381	CcSEcCtD
Mefenamic acid—Vascular purpura—Epirubicin—liver cancer	0.000583	0.00375	CcSEcCtD
Mefenamic acid—Hepatic failure—Epirubicin—liver cancer	0.00058	0.00373	CcSEcCtD
Mefenamic acid—Sepsis—Doxorubicin—liver cancer	0.000577	0.00371	CcSEcCtD
Mefenamic acid—Cardiac failure congestive—Epirubicin—liver cancer	0.000575	0.0037	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Sorafenib—liver cancer	0.000567	0.00365	CcSEcCtD
Mefenamic acid—Lymphadenopathy—Doxorubicin—liver cancer	0.000565	0.00364	CcSEcCtD
Mefenamic acid—Dermatitis exfoliative—Epirubicin—liver cancer	0.000553	0.00355	CcSEcCtD
Mefenamic acid—Urticaria—Sorafenib—liver cancer	0.000551	0.00354	CcSEcCtD
Mefenamic acid—Photosensitivity—Doxorubicin—liver cancer	0.000549	0.00353	CcSEcCtD
Mefenamic acid—Abdominal pain—Sorafenib—liver cancer	0.000548	0.00352	CcSEcCtD
Mefenamic acid—Body temperature increased—Sorafenib—liver cancer	0.000548	0.00352	CcSEcCtD
Mefenamic acid—Renal impairment—Epirubicin—liver cancer	0.000548	0.00352	CcSEcCtD
Mefenamic acid—Purpura—Epirubicin—liver cancer	0.000541	0.00348	CcSEcCtD
Mefenamic acid—Vascular purpura—Doxorubicin—liver cancer	0.000539	0.00347	CcSEcCtD
Mefenamic acid—Anaphylactoid reaction—Epirubicin—liver cancer	0.000539	0.00346	CcSEcCtD
Mefenamic acid—Hepatic failure—Doxorubicin—liver cancer	0.000537	0.00345	CcSEcCtD
Mefenamic acid—Cardiac failure congestive—Doxorubicin—liver cancer	0.000532	0.00342	CcSEcCtD
Mefenamic acid—Hyponatraemia—Epirubicin—liver cancer	0.000523	0.00337	CcSEcCtD
Mefenamic acid—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.000521	0.00335	CcSEcCtD
Mefenamic acid—Dermatitis exfoliative—Doxorubicin—liver cancer	0.000511	0.00329	CcSEcCtD
Mefenamic acid—Renal impairment—Doxorubicin—liver cancer	0.000507	0.00326	CcSEcCtD
Mefenamic acid—Purpura—Doxorubicin—liver cancer	0.000501	0.00322	CcSEcCtD
Mefenamic acid—Anaphylactoid reaction—Doxorubicin—liver cancer	0.000498	0.00321	CcSEcCtD
Mefenamic acid—Asthenia—Sorafenib—liver cancer	0.000497	0.0032	CcSEcCtD
Mefenamic acid—Pruritus—Sorafenib—liver cancer	0.000491	0.00315	CcSEcCtD
Mefenamic acid—Hyponatraemia—Doxorubicin—liver cancer	0.000484	0.00311	CcSEcCtD
Mefenamic acid—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.000482	0.0031	CcSEcCtD
Mefenamic acid—Liver function test abnormal—Epirubicin—liver cancer	0.000481	0.0031	CcSEcCtD
Mefenamic acid—Diarrhoea—Sorafenib—liver cancer	0.000474	0.00305	CcSEcCtD
Mefenamic acid—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.000469	0.00302	CcSEcCtD
Mefenamic acid—Gastritis—Epirubicin—liver cancer	0.000461	0.00297	CcSEcCtD
Mefenamic acid—Diclofenac—CYP2E1—liver cancer	0.00046	0.0998	CrCbGaD
Mefenamic acid—Dizziness—Sorafenib—liver cancer	0.000459	0.00295	CcSEcCtD
Mefenamic acid—Diclofenac—CYP1A1—liver cancer	0.000454	0.0985	CrCbGaD
Mefenamic acid—Asthma—Epirubicin—liver cancer	0.000451	0.0029	CcSEcCtD
Mefenamic acid—Eosinophilia—Epirubicin—liver cancer	0.000446	0.00287	CcSEcCtD
Mefenamic acid—Liver function test abnormal—Doxorubicin—liver cancer	0.000445	0.00286	CcSEcCtD
Mefenamic acid—Pancreatitis—Epirubicin—liver cancer	0.000442	0.00284	CcSEcCtD
Mefenamic acid—Vomiting—Sorafenib—liver cancer	0.000441	0.00284	CcSEcCtD
Mefenamic acid—Rash—Sorafenib—liver cancer	0.000437	0.00281	CcSEcCtD
Mefenamic acid—Dermatitis—Sorafenib—liver cancer	0.000437	0.00281	CcSEcCtD
Mefenamic acid—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.000434	0.00279	CcSEcCtD
Mefenamic acid—Headache—Sorafenib—liver cancer	0.000434	0.00279	CcSEcCtD
Mefenamic acid—Pancytopenia—Epirubicin—liver cancer	0.000428	0.00275	CcSEcCtD
Mefenamic acid—Gastritis—Doxorubicin—liver cancer	0.000427	0.00275	CcSEcCtD
Mefenamic acid—Dysuria—Epirubicin—liver cancer	0.000421	0.00271	CcSEcCtD
Mefenamic acid—Asthma—Doxorubicin—liver cancer	0.000417	0.00268	CcSEcCtD
Mefenamic acid—Eosinophilia—Doxorubicin—liver cancer	0.000413	0.00265	CcSEcCtD
Mefenamic acid—Nausea—Sorafenib—liver cancer	0.000412	0.00265	CcSEcCtD
Mefenamic acid—Photosensitivity reaction—Epirubicin—liver cancer	0.000411	0.00265	CcSEcCtD
Mefenamic acid—Pancreatitis—Doxorubicin—liver cancer	0.000409	0.00263	CcSEcCtD
Mefenamic acid—Hyperglycaemia—Epirubicin—liver cancer	0.000406	0.00261	CcSEcCtD
Mefenamic acid—Pneumonia—Epirubicin—liver cancer	0.000404	0.0026	CcSEcCtD
Mefenamic acid—Drowsiness—Epirubicin—liver cancer	0.000402	0.00258	CcSEcCtD
Mefenamic acid—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000398	0.00256	CcSEcCtD
Mefenamic acid—Pancytopenia—Doxorubicin—liver cancer	0.000396	0.00255	CcSEcCtD
Mefenamic acid—Renal failure—Epirubicin—liver cancer	0.000395	0.00254	CcSEcCtD
Mefenamic acid—Stomatitis—Epirubicin—liver cancer	0.000392	0.00252	CcSEcCtD
Mefenamic acid—Jaundice—Epirubicin—liver cancer	0.000392	0.00252	CcSEcCtD
Mefenamic acid—Conjunctivitis—Epirubicin—liver cancer	0.000391	0.00251	CcSEcCtD
Mefenamic acid—Dysuria—Doxorubicin—liver cancer	0.00039	0.00251	CcSEcCtD
Mefenamic acid—Haematuria—Epirubicin—liver cancer	0.000383	0.00246	CcSEcCtD
Mefenamic acid—Photosensitivity reaction—Doxorubicin—liver cancer	0.000381	0.00245	CcSEcCtD
Mefenamic acid—Fenoprofen—ALB—liver cancer	0.00038	0.0823	CrCbGaD
Mefenamic acid—Hyperglycaemia—Doxorubicin—liver cancer	0.000376	0.00242	CcSEcCtD
Mefenamic acid—Agranulocytosis—Epirubicin—liver cancer	0.000375	0.00241	CcSEcCtD
Mefenamic acid—Pneumonia—Doxorubicin—liver cancer	0.000374	0.0024	CcSEcCtD
Mefenamic acid—Drowsiness—Doxorubicin—liver cancer	0.000372	0.00239	CcSEcCtD
Mefenamic acid—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000369	0.00237	CcSEcCtD
Mefenamic acid—Renal failure—Doxorubicin—liver cancer	0.000365	0.00235	CcSEcCtD
Mefenamic acid—Haemoglobin—Epirubicin—liver cancer	0.000363	0.00233	CcSEcCtD
Mefenamic acid—Stomatitis—Doxorubicin—liver cancer	0.000362	0.00233	CcSEcCtD
Mefenamic acid—Jaundice—Doxorubicin—liver cancer	0.000362	0.00233	CcSEcCtD
Mefenamic acid—Conjunctivitis—Doxorubicin—liver cancer	0.000361	0.00232	CcSEcCtD
Mefenamic acid—Hepatitis—Epirubicin—liver cancer	0.000361	0.00232	CcSEcCtD
Mefenamic acid—Haemorrhage—Epirubicin—liver cancer	0.000361	0.00232	CcSEcCtD
Mefenamic acid—Urinary tract disorder—Epirubicin—liver cancer	0.000356	0.00229	CcSEcCtD
Mefenamic acid—Haematuria—Doxorubicin—liver cancer	0.000354	0.00228	CcSEcCtD
Mefenamic acid—Urethral disorder—Epirubicin—liver cancer	0.000354	0.00227	CcSEcCtD
Mefenamic acid—Agranulocytosis—Doxorubicin—liver cancer	0.000347	0.00223	CcSEcCtD
Mefenamic acid—Acetylsalicylic acid—ALB—liver cancer	0.000343	0.0744	CrCbGaD
Mefenamic acid—Erythema multiforme—Epirubicin—liver cancer	0.000341	0.00219	CcSEcCtD
Mefenamic acid—Tinnitus—Epirubicin—liver cancer	0.000336	0.00216	CcSEcCtD
Mefenamic acid—Haemoglobin—Doxorubicin—liver cancer	0.000335	0.00216	CcSEcCtD
Mefenamic acid—Haemorrhage—Doxorubicin—liver cancer	0.000334	0.00215	CcSEcCtD
Mefenamic acid—Hepatitis—Doxorubicin—liver cancer	0.000334	0.00215	CcSEcCtD
Mefenamic acid—Urinary tract disorder—Doxorubicin—liver cancer	0.00033	0.00212	CcSEcCtD
Mefenamic acid—Urethral disorder—Doxorubicin—liver cancer	0.000327	0.0021	CcSEcCtD
Mefenamic acid—Arrhythmia—Epirubicin—liver cancer	0.000322	0.00207	CcSEcCtD
Mefenamic acid—Alopecia—Epirubicin—liver cancer	0.000319	0.00205	CcSEcCtD
Mefenamic acid—Mental disorder—Epirubicin—liver cancer	0.000316	0.00203	CcSEcCtD
Mefenamic acid—Erythema multiforme—Doxorubicin—liver cancer	0.000316	0.00203	CcSEcCtD
Mefenamic acid—Tinnitus—Doxorubicin—liver cancer	0.000311	0.002	CcSEcCtD
Mefenamic acid—Flatulence—Epirubicin—liver cancer	0.000309	0.00199	CcSEcCtD
Mefenamic acid—Tension—Epirubicin—liver cancer	0.000308	0.00198	CcSEcCtD
Mefenamic acid—Nervousness—Epirubicin—liver cancer	0.000305	0.00196	CcSEcCtD
Mefenamic acid—Arrhythmia—Doxorubicin—liver cancer	0.000298	0.00192	CcSEcCtD
Mefenamic acid—Vision blurred—Epirubicin—liver cancer	0.000296	0.0019	CcSEcCtD
Mefenamic acid—Alopecia—Doxorubicin—liver cancer	0.000295	0.0019	CcSEcCtD
Mefenamic acid—Mental disorder—Doxorubicin—liver cancer	0.000292	0.00188	CcSEcCtD
Mefenamic acid—Ill-defined disorder—Epirubicin—liver cancer	0.000291	0.00187	CcSEcCtD
Mefenamic acid—Anaemia—Epirubicin—liver cancer	0.00029	0.00187	CcSEcCtD
Mefenamic acid—Flatulence—Doxorubicin—liver cancer	0.000286	0.00184	CcSEcCtD
Mefenamic acid—Tension—Doxorubicin—liver cancer	0.000285	0.00183	CcSEcCtD
Mefenamic acid—Malaise—Epirubicin—liver cancer	0.000283	0.00182	CcSEcCtD
Mefenamic acid—Salicylic acid—ALB—liver cancer	0.000282	0.0612	CrCbGaD
Mefenamic acid—Nervousness—Doxorubicin—liver cancer	0.000282	0.00181	CcSEcCtD
Mefenamic acid—Vertigo—Epirubicin—liver cancer	0.000282	0.00181	CcSEcCtD
Mefenamic acid—Syncope—Epirubicin—liver cancer	0.000282	0.00181	CcSEcCtD
Mefenamic acid—Leukopenia—Epirubicin—liver cancer	0.000281	0.00181	CcSEcCtD
Mefenamic acid—Palpitations—Epirubicin—liver cancer	0.000277	0.00178	CcSEcCtD
Mefenamic acid—Loss of consciousness—Epirubicin—liver cancer	0.000276	0.00177	CcSEcCtD
Mefenamic acid—Vision blurred—Doxorubicin—liver cancer	0.000274	0.00176	CcSEcCtD
Mefenamic acid—Convulsion—Epirubicin—liver cancer	0.000272	0.00175	CcSEcCtD
Mefenamic acid—Hypertension—Epirubicin—liver cancer	0.000271	0.00174	CcSEcCtD
Mefenamic acid—Ill-defined disorder—Doxorubicin—liver cancer	0.00027	0.00173	CcSEcCtD
Mefenamic acid—Anaemia—Doxorubicin—liver cancer	0.000269	0.00173	CcSEcCtD
Mefenamic acid—Anxiety—Epirubicin—liver cancer	0.000266	0.00171	CcSEcCtD
Mefenamic acid—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000265	0.00171	CcSEcCtD
Mefenamic acid—Discomfort—Epirubicin—liver cancer	0.000264	0.0017	CcSEcCtD
Mefenamic acid—Malaise—Doxorubicin—liver cancer	0.000262	0.00168	CcSEcCtD
Mefenamic acid—Dry mouth—Epirubicin—liver cancer	0.000261	0.00168	CcSEcCtD
Mefenamic acid—Vertigo—Doxorubicin—liver cancer	0.000261	0.00168	CcSEcCtD
Mefenamic acid—Syncope—Doxorubicin—liver cancer	0.000261	0.00168	CcSEcCtD
Mefenamic acid—Leukopenia—Doxorubicin—liver cancer	0.00026	0.00167	CcSEcCtD
Mefenamic acid—Confusional state—Epirubicin—liver cancer	0.000258	0.00166	CcSEcCtD
Mefenamic acid—Palpitations—Doxorubicin—liver cancer	0.000257	0.00165	CcSEcCtD
Mefenamic acid—Oedema—Epirubicin—liver cancer	0.000256	0.00165	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Epirubicin—liver cancer	0.000256	0.00165	CcSEcCtD
Mefenamic acid—Loss of consciousness—Doxorubicin—liver cancer	0.000255	0.00164	CcSEcCtD
Mefenamic acid—Infection—Epirubicin—liver cancer	0.000255	0.00164	CcSEcCtD
Mefenamic acid—Diclofenac—ALB—liver cancer	0.000253	0.0548	CrCbGaD
Mefenamic acid—Shock—Epirubicin—liver cancer	0.000252	0.00162	CcSEcCtD
Mefenamic acid—Convulsion—Doxorubicin—liver cancer	0.000252	0.00162	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Epirubicin—liver cancer	0.000251	0.00161	CcSEcCtD
Mefenamic acid—Hypertension—Doxorubicin—liver cancer	0.000251	0.00161	CcSEcCtD
Mefenamic acid—Tachycardia—Epirubicin—liver cancer	0.00025	0.00161	CcSEcCtD
Mefenamic acid—Skin disorder—Epirubicin—liver cancer	0.000249	0.0016	CcSEcCtD
Mefenamic acid—Flurbiprofen—ALB—liver cancer	0.000248	0.0537	CrCbGaD
Mefenamic acid—Anxiety—Doxorubicin—liver cancer	0.000246	0.00159	CcSEcCtD
Mefenamic acid—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000246	0.00158	CcSEcCtD
Mefenamic acid—Discomfort—Doxorubicin—liver cancer	0.000244	0.00157	CcSEcCtD
Mefenamic acid—Anorexia—Epirubicin—liver cancer	0.000244	0.00157	CcSEcCtD
Mefenamic acid—Dry mouth—Doxorubicin—liver cancer	0.000242	0.00156	CcSEcCtD
Mefenamic acid—Hypotension—Epirubicin—liver cancer	0.000239	0.00154	CcSEcCtD
Mefenamic acid—Confusional state—Doxorubicin—liver cancer	0.000239	0.00154	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Doxorubicin—liver cancer	0.000237	0.00152	CcSEcCtD
Mefenamic acid—Oedema—Doxorubicin—liver cancer	0.000237	0.00152	CcSEcCtD
Mefenamic acid—Infection—Doxorubicin—liver cancer	0.000236	0.00151	CcSEcCtD
Mefenamic acid—Shock—Doxorubicin—liver cancer	0.000233	0.0015	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Doxorubicin—liver cancer	0.000232	0.00149	CcSEcCtD
Mefenamic acid—Insomnia—Epirubicin—liver cancer	0.000232	0.00149	CcSEcCtD
Mefenamic acid—Tachycardia—Doxorubicin—liver cancer	0.000231	0.00149	CcSEcCtD
Mefenamic acid—Skin disorder—Doxorubicin—liver cancer	0.00023	0.00148	CcSEcCtD
Mefenamic acid—Paraesthesia—Epirubicin—liver cancer	0.00023	0.00148	CcSEcCtD
Mefenamic acid—Dyspnoea—Epirubicin—liver cancer	0.000228	0.00147	CcSEcCtD
Mefenamic acid—Somnolence—Epirubicin—liver cancer	0.000228	0.00147	CcSEcCtD
Mefenamic acid—Anorexia—Doxorubicin—liver cancer	0.000226	0.00145	CcSEcCtD
Mefenamic acid—Dyspepsia—Epirubicin—liver cancer	0.000226	0.00145	CcSEcCtD
Mefenamic acid—Ketoprofen—ALB—liver cancer	0.000224	0.0486	CrCbGaD
Mefenamic acid—Decreased appetite—Epirubicin—liver cancer	0.000223	0.00143	CcSEcCtD
Mefenamic acid—Hypotension—Doxorubicin—liver cancer	0.000222	0.00142	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Epirubicin—liver cancer	0.000221	0.00142	CcSEcCtD
Mefenamic acid—Constipation—Epirubicin—liver cancer	0.000219	0.00141	CcSEcCtD
Mefenamic acid—Insomnia—Doxorubicin—liver cancer	0.000214	0.00138	CcSEcCtD
Mefenamic acid—Paraesthesia—Doxorubicin—liver cancer	0.000213	0.00137	CcSEcCtD
Mefenamic acid—Dyspnoea—Doxorubicin—liver cancer	0.000211	0.00136	CcSEcCtD
Mefenamic acid—Feeling abnormal—Epirubicin—liver cancer	0.000211	0.00136	CcSEcCtD
Mefenamic acid—Somnolence—Doxorubicin—liver cancer	0.000211	0.00136	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Epirubicin—liver cancer	0.00021	0.00135	CcSEcCtD
Mefenamic acid—Dyspepsia—Doxorubicin—liver cancer	0.000209	0.00134	CcSEcCtD
Mefenamic acid—Decreased appetite—Doxorubicin—liver cancer	0.000206	0.00133	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000205	0.00132	CcSEcCtD
Mefenamic acid—Urticaria—Epirubicin—liver cancer	0.000204	0.00131	CcSEcCtD
Mefenamic acid—Constipation—Doxorubicin—liver cancer	0.000203	0.0013	CcSEcCtD
Mefenamic acid—Abdominal pain—Epirubicin—liver cancer	0.000203	0.0013	CcSEcCtD
Mefenamic acid—Body temperature increased—Epirubicin—liver cancer	0.000203	0.0013	CcSEcCtD
Mefenamic acid—Feeling abnormal—Doxorubicin—liver cancer	0.000195	0.00126	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Doxorubicin—liver cancer	0.000194	0.00125	CcSEcCtD
Mefenamic acid—Urticaria—Doxorubicin—liver cancer	0.000188	0.00121	CcSEcCtD
Mefenamic acid—Abdominal pain—Doxorubicin—liver cancer	0.000187	0.00121	CcSEcCtD
Mefenamic acid—Body temperature increased—Doxorubicin—liver cancer	0.000187	0.00121	CcSEcCtD
Mefenamic acid—Asthenia—Epirubicin—liver cancer	0.000184	0.00118	CcSEcCtD
Mefenamic acid—Pruritus—Epirubicin—liver cancer	0.000181	0.00117	CcSEcCtD
Mefenamic acid—Diarrhoea—Epirubicin—liver cancer	0.000175	0.00113	CcSEcCtD
Mefenamic acid—Asthenia—Doxorubicin—liver cancer	0.00017	0.00109	CcSEcCtD
Mefenamic acid—Dizziness—Epirubicin—liver cancer	0.000169	0.00109	CcSEcCtD
Mefenamic acid—Pruritus—Doxorubicin—liver cancer	0.000168	0.00108	CcSEcCtD
Mefenamic acid—Vomiting—Epirubicin—liver cancer	0.000163	0.00105	CcSEcCtD
Mefenamic acid—Diarrhoea—Doxorubicin—liver cancer	0.000162	0.00104	CcSEcCtD
Mefenamic acid—Rash—Epirubicin—liver cancer	0.000162	0.00104	CcSEcCtD
Mefenamic acid—Dermatitis—Epirubicin—liver cancer	0.000161	0.00104	CcSEcCtD
Mefenamic acid—Headache—Epirubicin—liver cancer	0.000161	0.00103	CcSEcCtD
Mefenamic acid—Dizziness—Doxorubicin—liver cancer	0.000157	0.00101	CcSEcCtD
Mefenamic acid—Nausea—Epirubicin—liver cancer	0.000152	0.000979	CcSEcCtD
Mefenamic acid—Vomiting—Doxorubicin—liver cancer	0.000151	0.000969	CcSEcCtD
Mefenamic acid—Rash—Doxorubicin—liver cancer	0.000149	0.000961	CcSEcCtD
Mefenamic acid—Dermatitis—Doxorubicin—liver cancer	0.000149	0.000961	CcSEcCtD
Mefenamic acid—Headache—Doxorubicin—liver cancer	0.000149	0.000955	CcSEcCtD
Mefenamic acid—Nausea—Doxorubicin—liver cancer	0.000141	0.000906	CcSEcCtD
Mefenamic acid—AKR1C3—Metabolism—PPARG—liver cancer	3.58e-05	0.000173	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—GSTA1—liver cancer	3.53e-05	0.000171	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	3.53e-05	0.000171	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—MTOR—liver cancer	3.53e-05	0.000171	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—PIK3CB—liver cancer	3.53e-05	0.000171	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CPT1B—liver cancer	3.52e-05	0.000171	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—GLUL—liver cancer	3.52e-05	0.000171	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—HPGDS—liver cancer	3.52e-05	0.00017	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metabolism—PIK3CA—liver cancer	3.51e-05	0.00017	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	3.5e-05	0.00017	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—PPARG—liver cancer	3.5e-05	0.000169	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—NAT2—liver cancer	3.49e-05	0.000169	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—RAF1—liver cancer	3.47e-05	0.000168	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—NR1H4—liver cancer	3.4e-05	0.000165	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—MTOR—liver cancer	3.39e-05	0.000164	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—PIK3CB—liver cancer	3.39e-05	0.000164	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—KDR—liver cancer	3.36e-05	0.000163	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	3.36e-05	0.000163	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—ALDOB—liver cancer	3.35e-05	0.000162	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—KRAS—liver cancer	3.34e-05	0.000162	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—MAPK14—liver cancer	3.34e-05	0.000162	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—GSTA3—liver cancer	3.34e-05	0.000162	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—CDKN1B—liver cancer	3.31e-05	0.00016	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—ESR1—liver cancer	3.28e-05	0.000159	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—PIK3CD—liver cancer	3.26e-05	0.000158	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—CASP3—liver cancer	3.25e-05	0.000157	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—IL2—liver cancer	3.24e-05	0.000157	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—F2—liver cancer	3.24e-05	0.000157	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	3.22e-05	0.000156	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—ALB—liver cancer	3.22e-05	0.000156	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—CRABP1—liver cancer	3.19e-05	0.000155	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	3.18e-05	0.000154	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—CDKN1B—liver cancer	3.18e-05	0.000154	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—ADAM17—liver cancer	3.16e-05	0.000153	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—CCND1—liver cancer	3.16e-05	0.000153	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—JUN—liver cancer	3.15e-05	0.000153	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—ALB—liver cancer	3.14e-05	0.000152	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PSMD10—liver cancer	3.13e-05	0.000152	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PSMA4—liver cancer	3.13e-05	0.000152	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—CTNNB1—liver cancer	3.13e-05	0.000152	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	3.11e-05	0.000151	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—liver cancer	3.11e-05	0.000151	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—APC—liver cancer	3.1e-05	0.00015	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—PIK3CG—liver cancer	3.1e-05	0.00015	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—PIK3CA—liver cancer	3.07e-05	0.000149	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—MMP9—liver cancer	3.07e-05	0.000149	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—GSTA4—liver cancer	3.06e-05	0.000148	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—CDKN1A—liver cancer	3.06e-05	0.000148	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—GOT2—liver cancer	3.05e-05	0.000148	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—CTNNB1—liver cancer	3.01e-05	0.000146	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	2.99e-05	0.000145	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—MAPK8—liver cancer	2.98e-05	0.000145	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—GSTA2—liver cancer	2.98e-05	0.000144	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PSMD10—liver cancer	2.97e-05	0.000144	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PSMA4—liver cancer	2.97e-05	0.000144	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—CDKN1A—liver cancer	2.94e-05	0.000142	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—BRAF—liver cancer	2.91e-05	0.000141	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—GOT2—liver cancer	2.89e-05	0.00014	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	2.88e-05	0.000139	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—GSTA1—liver cancer	2.87e-05	0.000139	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GLUL—liver cancer	2.87e-05	0.000139	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CPT1B—liver cancer	2.87e-05	0.000139	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—CYP2E1—liver cancer	2.87e-05	0.000139	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metabolism—AKT1—liver cancer	2.86e-05	0.000139	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—HRAS—liver cancer	2.84e-05	0.000138	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—NAT2—liver cancer	2.84e-05	0.000138	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—PIK3CB—liver cancer	2.84e-05	0.000138	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—HPGDS—liver cancer	2.79e-05	0.000135	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	2.78e-05	0.000134	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	2.78e-05	0.000134	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—NR1H4—liver cancer	2.77e-05	0.000134	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—VEGFA—liver cancer	2.75e-05	0.000133	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PPARA—liver cancer	2.73e-05	0.000132	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—STAT3—liver cancer	2.73e-05	0.000132	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—PIK3CD—liver cancer	2.72e-05	0.000132	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—ALDOB—liver cancer	2.72e-05	0.000132	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—IL6—liver cancer	2.72e-05	0.000132	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GSTA3—liver cancer	2.72e-05	0.000132	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—SERPINE1—liver cancer	2.69e-05	0.000131	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—CYCS—liver cancer	2.68e-05	0.00013	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—GOT1—liver cancer	2.63e-05	0.000128	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—GGT1—liver cancer	2.63e-05	0.000128	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	2.63e-05	0.000127	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—STAT3—liver cancer	2.62e-05	0.000127	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CRABP1—liver cancer	2.6e-05	0.000126	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—PIK3CA—liver cancer	2.57e-05	0.000125	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—MYC—liver cancer	2.53e-05	0.000123	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—TGFB1—liver cancer	2.53e-05	0.000122	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	2.53e-05	0.000122	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—AKT1—liver cancer	2.51e-05	0.000122	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—ALB—liver cancer	2.5e-05	0.000121	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—GOT1—liver cancer	2.49e-05	0.000121	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PSMA4—liver cancer	2.49e-05	0.000121	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PSMD10—liver cancer	2.49e-05	0.000121	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GSTA4—liver cancer	2.49e-05	0.000121	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—MYC—liver cancer	2.44e-05	0.000118	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—RAF1—liver cancer	2.43e-05	0.000118	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	2.43e-05	0.000118	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—TGFB1—liver cancer	2.43e-05	0.000118	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GSTA2—liver cancer	2.42e-05	0.000117	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—GOT2—liver cancer	2.42e-05	0.000117	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—MTOR—liver cancer	2.37e-05	0.000115	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—PIK3CB—liver cancer	2.37e-05	0.000115	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—GSTP1—liver cancer	2.36e-05	0.000115	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—KRAS—liver cancer	2.34e-05	0.000113	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	2.34e-05	0.000113	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GSTA1—liver cancer	2.34e-05	0.000113	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—HMOX1—liver cancer	2.33e-05	0.000113	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—NAT2—liver cancer	2.31e-05	0.000112	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PRKCE—liver cancer	2.3e-05	0.000112	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—CYP2E1—liver cancer	2.28e-05	0.00011	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—HPGDS—liver cancer	2.27e-05	0.00011	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—liver cancer	2.26e-05	0.000109	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—KRAS—liver cancer	2.25e-05	0.000109	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CDKN1B—liver cancer	2.23e-05	0.000108	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	2.22e-05	0.000108	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—ALDOB—liver cancer	2.22e-05	0.000107	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	2.2e-05	0.000107	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CASP3—liver cancer	2.18e-05	0.000106	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—IL2—liver cancer	2.18e-05	0.000106	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—GSTM1—liver cancer	2.17e-05	0.000105	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—PIK3CA—liver cancer	2.15e-05	0.000104	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—CYCS—liver cancer	2.13e-05	0.000103	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CCND1—liver cancer	2.13e-05	0.000103	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—JUN—liver cancer	2.12e-05	0.000103	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CRABP1—liver cancer	2.11e-05	0.000102	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CTNNB1—liver cancer	2.11e-05	0.000102	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—AKT1—liver cancer	2.1e-05	0.000102	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—GOT1—liver cancer	2.09e-05	0.000101	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—GGT1—liver cancer	2.09e-05	0.000101	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—TP53—liver cancer	2.08e-05	0.000101	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—PIK3CA—liver cancer	2.07e-05	0.0001	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—MMP9—liver cancer	2.06e-05	0.0001	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—CYP1A1—liver cancer	2.06e-05	9.98e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	2.06e-05	9.97e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CDKN1A—liver cancer	2.06e-05	9.96e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—ALB—liver cancer	2.03e-05	9.84e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PSMA4—liver cancer	2.02e-05	9.81e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PSMD10—liver cancer	2.02e-05	9.81e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—MAPK8—liver cancer	2.01e-05	9.73e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—H2AFX—liver cancer	2.01e-05	9.72e-05	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—HRAS—liver cancer	1.99e-05	9.64e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—GOT2—liver cancer	1.97e-05	9.54e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—MTHFR—liver cancer	1.92e-05	9.3e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—HRAS—liver cancer	1.91e-05	9.27e-05	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—IL6—liver cancer	1.9e-05	9.23e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	1.9e-05	9.23e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PPARA—liver cancer	1.88e-05	9.13e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—GSTP1—liver cancer	1.88e-05	9.09e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—VEGFA—liver cancer	1.85e-05	8.98e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CYP2E1—liver cancer	1.85e-05	8.97e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—HMOX1—liver cancer	1.85e-05	8.97e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—HPGDS—liver cancer	1.85e-05	8.96e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.84e-05	8.9e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—STAT3—liver cancer	1.84e-05	8.89e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—IL6—liver cancer	1.83e-05	8.87e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—MTHFR—liver cancer	1.82e-05	8.82e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—TERT—liver cancer	1.81e-05	8.79e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.79e-05	8.69e-05	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—AKT1—liver cancer	1.76e-05	8.51e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CYCS—liver cancer	1.73e-05	8.39e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—PIK3CA—liver cancer	1.73e-05	8.39e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—GSTM1—liver cancer	1.72e-05	8.36e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—MYC—liver cancer	1.71e-05	8.26e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—TGFB1—liver cancer	1.7e-05	8.24e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—GGT1—liver cancer	1.7e-05	8.24e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—GOT1—liver cancer	1.7e-05	8.24e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.69e-05	8.2e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—AKT1—liver cancer	1.69e-05	8.18e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.67e-05	8.11e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	1.65e-05	8.01e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PSMA4—liver cancer	1.65e-05	7.98e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PSMD10—liver cancer	1.65e-05	7.98e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—CYP1A1—liver cancer	1.63e-05	7.92e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PIK3CG—liver cancer	1.61e-05	7.82e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GOT2—liver cancer	1.6e-05	7.77e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—KRAS—liver cancer	1.58e-05	7.63e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PPARG—liver cancer	1.56e-05	7.54e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—APC—liver cancer	1.53e-05	7.41e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—GSTP1—liver cancer	1.53e-05	7.4e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—MTHFR—liver cancer	1.52e-05	7.38e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CYP2E1—liver cancer	1.51e-05	7.3e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—HMOX1—liver cancer	1.51e-05	7.3e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PPARA—liver cancer	1.5e-05	7.24e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.46e-05	7.07e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—PIK3CA—liver cancer	1.45e-05	7.01e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—BRAF—liver cancer	1.44e-05	6.96e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PIK3CD—liver cancer	1.42e-05	6.87e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—AKT1—liver cancer	1.41e-05	6.85e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CYCS—liver cancer	1.41e-05	6.83e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—GSTM1—liver cancer	1.4e-05	6.8e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—TP53—liver cancer	1.4e-05	6.78e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—ALB—liver cancer	1.4e-05	6.78e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GOT1—liver cancer	1.38e-05	6.7e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GGT1—liver cancer	1.38e-05	6.7e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PIK3CD—liver cancer	1.34e-05	6.51e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.34e-05	6.51e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—HRAS—liver cancer	1.34e-05	6.49e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CYP1A1—liver cancer	1.33e-05	6.45e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—SERPINE1—liver cancer	1.33e-05	6.44e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—IL6—liver cancer	1.28e-05	6.21e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PIK3CG—liver cancer	1.28e-05	6.2e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GSTP1—liver cancer	1.24e-05	6.02e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—MTHFR—liver cancer	1.24e-05	6.01e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PIK3CB—liver cancer	1.24e-05	5.99e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PPARG—liver cancer	1.24e-05	5.99e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—HMOX1—liver cancer	1.23e-05	5.94e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PPARA—liver cancer	1.22e-05	5.89e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—RAF1—liver cancer	1.2e-05	5.81e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—AKT1—liver cancer	1.18e-05	5.73e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—MTOR—liver cancer	1.17e-05	5.68e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PIK3CB—liver cancer	1.17e-05	5.68e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GSTM1—liver cancer	1.14e-05	5.53e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PIK3CD—liver cancer	1.13e-05	5.45e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—ALB—liver cancer	1.11e-05	5.38e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—CDKN1B—liver cancer	1.1e-05	5.33e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.09e-05	5.3e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CYP1A1—liver cancer	1.08e-05	5.25e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PIK3CG—liver cancer	1.04e-05	5.05e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—CTNNB1—liver cancer	1.04e-05	5.03e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—CDKN1A—liver cancer	1.01e-05	4.92e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—MTHFR—liver cancer	1.01e-05	4.89e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PPARG—liver cancer	1.01e-05	4.87e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PPARA—liver cancer	9.9e-06	4.8e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PIK3CB—liver cancer	9.81e-06	4.75e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PIK3CD—liver cancer	9.16e-06	4.44e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—STAT3—liver cancer	9.06e-06	4.39e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—ALB—liver cancer	9.04e-06	4.38e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	8.89e-06	4.31e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PIK3CG—liver cancer	8.48e-06	4.11e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—MYC—liver cancer	8.41e-06	4.08e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—TGFB1—liver cancer	8.39e-06	4.07e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PPARG—liver cancer	8.18e-06	3.97e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PIK3CB—liver cancer	7.98e-06	3.87e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—KRAS—liver cancer	7.77e-06	3.77e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PIK3CA—liver cancer	7.54e-06	3.65e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PIK3CD—liver cancer	7.46e-06	3.61e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—ALB—liver cancer	7.36e-06	3.57e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PIK3CA—liver cancer	7.14e-06	3.46e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—HRAS—liver cancer	6.61e-06	3.2e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PIK3CB—liver cancer	6.5e-06	3.15e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—IL6—liver cancer	6.32e-06	3.06e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—AKT1—liver cancer	6.16e-06	2.98e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PIK3CA—liver cancer	5.98e-06	2.9e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—AKT1—liver cancer	5.84e-06	2.83e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—AKT1—liver cancer	4.89e-06	2.37e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PIK3CA—liver cancer	4.87e-06	2.36e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—AKT1—liver cancer	3.98e-06	1.93e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PIK3CA—liver cancer	3.96e-06	1.92e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—AKT1—liver cancer	3.24e-06	1.57e-05	CbGpPWpGaD
